ROBINS' RESPONSE TO THE SPEECH BY EIGHTH CIRCUIT JUDGE LORD
Judge Lord's comments are not surprising in view of his previously expressed dislike of corporate America. What is surprising and distressing is the fact that a federal judge has abandoned his role as an impartial arbiter and, acknowledging from the bench his prejudice against the company, become an open advocate for one side. As counsel for the company noted, the judge's comments, based on a selective review of only a part of the evidence that would have been presented had the cases been tried, constituted a gross abuse of judicial discreion and power. Contrary to the judge's accusation, the company believes it has acted responsibly in the handling of the Dalkon Shield. The court chose to overlook the fact that in September 1980 Robins mailed a letter, recommending the removal of the Dalkon Shield from any woman still using the device, to approximately 200,000 physicians, clinics and govt. agencies. At the same time a news release was distributed to major wire services and newspapers in order to make the general public aware of the recommendation. The company believes this action was an adequate means of informing both the medical profession and any remaining users of the device of the desirability of removal. It should be noted that the FDA utilized essentially the same channels of dissemination nearly three years later when it issued a recommendation for removal of the device from remaining users.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth